Aquinox Pharmaceuticals (canada) Inc.

Zenith Epigenetics Corp.

Aquinox Pharmaceuticals Inc.

Vladimir Khlebnikov

Curtis Harwig

Jeremy D Pettigrew

Rudong Shan

David Earl Bogucki

Jeffery R Raymond

Lloyd F Mackenzie

Thomas B MacRury

John Frederick Quinn

Lloyd Mackenzie

Paul Bird

Tom MacRury

Noor Aini Bhatti

Sam Place

The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.

Quinazolinones as bromodomain inhibitors

Compounds of formula (I): where n, R, R, R, R, Rand Rare defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

SHIP1 modulators and methods related thereto

The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy. 

Compounds of formula (I): where, n, R, R, R, R, Rand Rare defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. 

Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R, R, R, R, R, Rand Rare as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

Growing community of inventors

Edmonton, Canada

Vladimir Khlebnikov